Why Endo (ENDP) Shares Are Plunging Today

Endo International plc's ENDP Q2 sales decreased 20% to $569.11 million, beating the consensus of $529.94 million.
The decrease was attributable to decreased revenues from the Sterile Injectables segment, partially offset by increased revenues from the Generic Pharmaceuticals segment.
Sterile Injectables segment revenues fell 58% to $123 million, primarily due to decreased Vasostrict revenues due to lower price and generic competition, channel inventory destocking, and lower overall market volumes as COVID-19-related hospitalizations decline.
The company remains in constructive negotiations with its creditors, and it expects that these negotiations will likely result in a pre-arranged filing under Chapter 11 Bankruptcy.
Also Read: Endo Weighing Chapter 11 Filing Before Junior Creditors, Opioid Settlements: Report.
Generic segment revenues were $203 million, up 22%, attributable to revenues from varenicline tablets.
Adjusted income from continuing operations fell 96% to $6.5 million.
Adjusted EPS reached $0.03 compared to $0.62 a year ago.
Branded pharma segment revenues were $219 million, a decrease of 4%. Specialty Products revenues decreased 2% to $164 million, with Xiaflex increasing 8% to $121 million.
Price Action: ENDP shares are down 41.39% at $0.39 during the market session on the last check Tuesday.

Endo Shares Plunge On Imminent Bankruptcy Filing